KLRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Kalaris Therapeutics Inc (KLRS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has potential upside based on analyst ratings and its lead candidate TH103, the company's poor financial performance and lack of significant trading trends make it a less compelling investment right now. Waiting for further developments or improved financials may be prudent.
The technical indicators show mixed signals. The MACD is positive and contracting, suggesting a potential upward trend. The RSI is neutral at 57.893, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock's price is currently near its resistance level (R1: 10.964), which could limit immediate upside potential.
Analyst ratings are positive, with a Buy rating and price targets of $19 and $26, citing the commercial potential of TH103 in addressing significant medical conditions. The stock has a bullish moving average pattern, and the MACD is positive.
There are no significant trading trends from hedge funds or insiders, and no recent news or Congress trading data to act as a catalyst.
In Q3 2025, the company's revenue remained at 0 with no growth. Net income dropped significantly to -$11.89M (-68.77% YoY), and EPS fell to -0.64 (-97.73% YoY). Gross margin remained at 0 with no improvement.
Analysts are optimistic about KLRS, with a Buy rating and price targets of $19 and $26. The commercial potential of TH103 in treating wet age-related macular degeneration and other conditions is seen as a key driver for the stock. Analysts view any weakness as a buying opportunity.
